Skip Navigation
National Institute of Environmental Health SciencesNational Institutes of Health
Increase text size Decrease text size Print this page

IMACS Publications

  1. Rider LG, Lachenbruch P, Isenberg DA, Miller FW, Applicability of the paediatric rheumatology international trials organisation disease activity core set for juvenile dermatomyositis: comment on the article by Ruperto et al., Arthritis Rheum, 2008 Aug 15 59(8):1197-8
    Pub Med (http://www.ncbi.nlm.nih.gov/pubmed/18668578?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum)
  2. Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, Feldman BM, Giannini EH, Miller FW, International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies, Arthritis Rheum, 2005 Sep 52(9):2607-2615
    Pub Med (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16142757&query_hl=3)
  3. Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, Lachenbruch PA, Miller FWInternational Myositis Assessment and Clinical Studies Group, International Consensus On Preliminary Definitions of Improvement for Adult and Juvenile Myositis, Arthritis Rheum, 2004 Jul 50(7):2281-90
    Pub Med (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15248228)
  4. Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, Lachenbruch PA, Miller FWInternational Myositis Assessment and Clinical Studies Group, Defining Clinical Improvement in Adult and Juvenile Myositis, J Rheumatol, 2003 Mar 30(3):603-17
    Pub Med (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12610824&dopt=Abstract)
  5. Isenberg DA, Allen E, Farewell V, Ehrenstein M, Hanna MG, Lundberg IE, Oddis C, Pilkington C, Plotz P, Scott D, Venkovsky J, Rider L, Miller F.for the International Myositis and Clinical Studies Group (IMACS), International consensus outcome measures for patients with idiopathic inflammatory myopathies: Development and initial validation of myositis activity and damage indices in patients with adult onset disease, Rheumatology, 2003 42: 1 - 7
    Pub Med (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12867580&dopt=Abstract)
  6. Rider LGInternational Myositis Outcome Assessment Collaborative Study Group, Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies, Rheum Dis Clin North Am, 2002 Nov 28(4):935-77
    Pub Med (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12506779&dopt=Abstract)
  7. Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, Lundberg I, Morrison C, Oakley L, Oakley I, Pilkington C, Vencovsky J, Vincent K, Scott DL, Isenberg DA, Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies, Rheum Dis Clin North Am, 2001 Nov 40(11):1262-73
    Pub Med (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11709610&dopt=Abstract)
USA.gov Department of Health & Human Services National Institutes of Health
This page URL: http://www.niehs.nih.gov/research/resources/collab/imacs/imacspubs.cfm
NIEHS website: http://www.niehs.nih.gov/
Email the Web Manager at webmanager@niehs.nih.gov
Last Reviewed: October 30, 2007